睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07380646,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed unilateral primary invasive breast cancer, with the date of initial cytological or histological diagnosis within 18 months before enrollment. Patients with multicentric and/or multifocal tumors are eligible if all pathologically examined lesions meet criteria 5 and 6 below.

    入选标准第 4 条

  3. Evidence of distant metastasis of breast cancer beyond regional lymph nodes (AJCC 8th edition Stage IV) and/or recurrence after curative surgery.

    排除标准第 5 条

  4. Contraception must be continued during the trial treatment and for 21 days after treatment discontinuation.

    入选标准第 18 条

    Previous treatment with any CDK4/6 inhibitor.

    排除标准第 1 条

    Clinical and laboratory acute toxicities related to prior anticancer therapy have not recovered to Grade 1 or lower (per NCI CTCAE version 4.03) on the day of enrollment. Exceptions: alopecia and amenorrhea of any grade are allowed.

    排除标准第 8 条

  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

    入选标准第 12 条

  6. Treatment with immunomodulators or other drugs affecting leukocytes (e.g., thymosin, batyl alcohol, IL-11, GM-CSF, G-CSF) within ≤ 4 weeks before starting trial treatment.

    排除标准第 15 条

    Complete blood count within 1 week before ribociclib administration showing white blood cell or neutrophil count below the lower limit of normal of the testing institution.

    排除标准第 19 条

  7. Use of tamoxifen, raloxifene, or aromatase inhibitors for breast cancer risk reduction ("chemoprevention") and/or osteoporosis treatment within 2 years before signing informed consent.

    排除标准第 2 条

    Known history of human immunodeficiency virus (HIV) infection.

    排除标准第 10 条

    Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

    排除标准第 11 条

  8. Pregnancy or lactation, or planning to become pregnant or breastfeed during the trial period.

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07380646,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The patient has signed and dated the informed consent form.
  2. Age > 18 years at the time of signing informed consent.
  3. The patient is a female with known menopausal status at the time of signing informed consent or initiation of adjuvant endocrine therapy (whichever is earlier). Postmenopausal status is defined as: bilateral oophorectomy, age > 60 years, or age < 60 years with amenorrhea ≥ 12 months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression), and follicle-stimulating hormone and plasma estradiol levels within the local postmenopausal normal range.
  4. Histologically confirmed unilateral primary invasive breast cancer, with the date of initial cytological or histological diagnosis within 18 months before enrollment. Patients with multicentric and/or multifocal tumors are eligible if all pathologically examined lesions meet criteria 5 and 6 below.
  5. Estrogen receptor (ER) and/or progesterone receptor (PgR) positivity in the breast cancer, based on the most recent analyzed tissue sample from the local laboratory.
  6. HER2-negative breast cancer, defined as negative by in situ hybridization or immunohistochemistry (IHC) status of 0 or 1+. If IHC is 2+, a negative in situ hybridization result is required to confirm HER2-negative status (based on the most recent analyzed tissue sample from the local laboratory).
  7. The patient has undergone surgical resection with complete tumor removal, negative microscopic margins on the final surgical specimen, and belongs to one of the following categories:
  8. If clinically indicated, the patient has completed adjuvant and/or neoadjuvant chemotherapy according to guidelines before screening.
  9. If clinically indicated, the patient has completed adjuvant radiotherapy according to guidelines before screening.
  10. The patient has no contraindications to the adjuvant endocrine therapy in the trial and plans to receive endocrine therapy for 5 years or longer starting from the randomization date.
  11. The patient may have received any standard neoadjuvant endocrine therapy at the time of signing informed consent, but enrollment must occur within 12 months of the first endocrine therapy initiation. Note: Endocrine therapy for ovarian suppression or short-term fertility preservation is not considered neoadjuvant/adjuvant endocrine therapy. If the patient is using tamoxifen as adjuvant endocrine therapy, a washout period of 5 half-lives is required before enrollment, during which the patient may take an aromatase inhibitor.
  12. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  13. Adequate bone marrow and organ function defined by meeting the following local laboratory values:
  14. The following laboratory parameters must be within normal limits or corrected to normal range with supplementation (corrected local laboratory values should be recorded as normal):
  15. Standard 12-lead electrocardiogram assessed by the local institution meeting the following:
  16. The patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
  17. Females of childbearing potential must have a negative serum pregnancy test (for β-hCG) within 14 days before enrollment. Females of childbearing potential must be willing to use highly effective contraception. A female is considered to be of childbearing potential unless she has had natural amenorrhea for 12 months with appropriate clinical features (i.e., age-appropriate history of vasomotor symptoms), or has undergone bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before randomization. In the case of oophorectomy alone, only after the female's reproductive status has been confirmed by subsequent hormone level assessment is she considered not of childbearing potential.
  18. Contraception must be continued during the trial treatment and for 21 days after treatment discontinuation.

排除标准:Exclusion Criteria:

  1. Previous treatment with any CDK4/6 inhibitor.
  2. Use of tamoxifen, raloxifene, or aromatase inhibitors for breast cancer risk reduction ("chemoprevention") and/or osteoporosis treatment within 2 years before signing informed consent.
  3. Prior anthracycline cumulative dose reaching or exceeding: doxorubicin 450 mg/m², or epirubicin 900 mg/m².
  4. Known hypersensitivity to any excipient of ribociclib and/or the endocrine therapy and/or leucogen (e.g., rare hereditary galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, or soy allergy).
  5. Evidence of distant metastasis of breast cancer beyond regional lymph nodes (AJCC 8th edition Stage IV) and/or recurrence after curative surgery.
  6. Concurrent use of other anticancer therapies, except adjuvant endocrine therapy.
  7. Major surgery, chemotherapy, or radiotherapy within 14 days before enrollment.
  8. Clinical and laboratory acute toxicities related to prior anticancer therapy have not recovered to Grade 1 or lower (per NCI CTCAE version 4.03) on the day of enrollment. Exceptions: alopecia and amenorrhea of any grade are allowed.
  9. Current invasive malignancy, or previous invasive malignancy completed treatment within 2 years before signing informed consent. Note: Patients with past or concurrent in situ malignancy are eligible if they have undergone adequate curative treatment before enrollment.
  10. Known history of human immunodeficiency virus (HIV) infection.
  11. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  12. Clinically significant, uncontrolled cardiac disease and/or cardiac repolarization abnormalities, including any of the following:
  13. Use of any of the following within 7 days before enrollment:
  14. Systemic corticosteroid therapy within ≤ 2 weeks before starting trial treatment, or not fully recovered from side effects of such therapy.
  15. Treatment with immunomodulators or other drugs affecting leukocytes (e.g., thymosin, batyl alcohol, IL-11, GM-CSF, G-CSF) within ≤ 4 weeks before starting trial treatment.
  16. Impaired gastrointestinal function or gastrointestinal disease that may significantly alter absorption of oral trial drugs (e.g., uncontrolled ulcerative disease, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, or small bowel resection).
  17. Any other concurrent severe and/or uncontrolled medical condition that, in the investigator's judgment, would pose an unacceptable safety risk, contraindicate participation in the clinical trial, or affect compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, cirrhosis or any other significant liver disease, active untreated or uncontrolled fungal, bacterial or viral infection, active infection requiring systemic antimicrobial therapy, etc.), or would limit life expectancy to ≤ 5 years.
  18. Participation in another interventional study with investigational product treatment (or use of an investigational device) within 30 days before enrollment, or within 5 half-lives of the investigational product (whichever is longer).
  19. Complete blood count within 1 week before ribociclib administration showing white blood cell or neutrophil count below the lower limit of normal of the testing institution.
  20. Pregnancy or lactation, or planning to become pregnant or breastfeed during the trial period.

引自 ClinicalTrials.gov, NCT07380646, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07380646,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07380646